Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 413-415

  Maurin, Max ^a   Bakken, Johan S ^b   Dumler, J Stephen ^b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CHLORAMPHENICOL; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; RIFAMPICIN;

ANAPLASMA PHAGOCYTOPHILUM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONCENTRATION RESPONSE; EHRLICHIA; EHRLICHIOSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; UNITED STATES;

ANAPLASMA PHAGOCYTOPHILUM; ANIMALS; ANTI-BACTERIAL AGENTS; DOGS; HORSES; HUMANS; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 0037227913     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.413-415.2003     Document Type: Article

References (34)

1. Aguero-Rosenfeld, M. E., H. W. Horowitz, G. P. Wormser, D. F. McKenna, J. Nowakowski, J. Munoz, and J. S. Dumler. 1996. Human granulocytic ehrlichiosis: a case series from a medical center in New York state. Ann. Intern. Med. 125:904-908.
2. Asanovich, K. M., J. S. Bakken, J. E. Madigan, M. Aguero-Rosenfeld, G. P. Wormser, and J. S. Dumler. 1997. Antigenic diversity of granulocytic Ehrlichia isolates from humans in Wisconsin and New York and a horse in California. J. Infect. Dis. 176:1029-1034.
3. Bakken, J. S., J. S. Dumler, S. M. Chen, M. R. Eckman, L. L. Van Etta, and D. H. Walker. 1994. Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging? JAMA 272:212-218.
4. Bakken, J. S., J. Kreuth, C. Wilson-Nordskog, R. L. Tilden, K. Asanovitch, and J. S. Dumler. 1996. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 275:199-205.
5. Brouqui, P., J. S. Dumler, R. Lienhard, M. Brossard, and D. Raoult. 1995. Human granulocytic ehrlichiosis in Europe. Lancet 346:782-783.
6. Brouqui, P., and D. Raoult. 1990. In vitro susceptibility of Ehrlichia sennetsu to antibiotics. Antimicrob. Agents Chemother. 34:1593-1596.
7. Brouqui, P., and D. Raoult. 1992. In vitro antibiotic susceptibility of the newly recognized agent of human ehrlichiosis, Ehrlichia chaffeensis. Antimicrob. Agents Chemother. 36:2799-2803.
8. Buitrago, M. I., J. W. Ijdo, P. Rinaudo, H. Simon, J. Copel, J. Gadbaw, R. Heimer, E. Fikrig, and F. J. Bia. 1998. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin. Infect. Dis. 27:213-215.
9. Dumler, J. S. 1997. Is human granulocytic ehrlichiosis a new Lyme disease? Review and comparison of clinical, laboratory, epidemiological, and some biological features. Clin. Infect. Dis. 25(Suppl. 1):S43-S47.
10. Dumler, J. S., K. M. Asanovich, J. S. Bakken, P. Richter, R. Kimsey, and J. E. Madigan. 1995. Serologic cross-reactions among Ehrlichia equi, Ehrlichia phagocytophila, and human granulocytic ehrlichia. J. Clin. Microbiol. 33:1098-1103.
11. Dumler, J. S., and J. S. Bakken. 1996. Human granulocytic ehrlichiosis in Wisconsin and Minnesota: a frequent infection with the potential for persistence. J. Infect. Dis. 173:1027-1030.
12. Dumler, J. S., and J. S. Bakken. 1995. Ehrlichial diseases of humans: emerging tick-borne infections. Clin. Infect. Dis. 20:1102-1110.
13. Dumler, J. S., and J. S. Bakken. 1998. Human ehrlichioses: newly recognized infections transmitted by ticks. Annu. Rev. Med. 49:201-213.
14. Dumler, J. S., A. F. Barbet, C. P. Bekker, G. A. Dasch, G. H. Palmer, S. C. Ray, Y. Rikihisa, and F. R. Rurangirwa. 2001. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila. Int. J. Syst. Evol. Microbiol. 51:2145-2165.
15. Enright, M., P. Zawadski, P. Pickerill, and C. G. Dowson. 1998. Molecular evolution of rifampicin resistance in Streptococcus pneumoniae. Microb. Drug Resist. 4:65-70.
16. Geerdes-Fenge, H. F., A. Wiedersich, S. Wagner, K. H. Lehr, P. Koeppe, and H. Lode. 2000. Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species. Antimicrob. Agents Chemother. 44:3478-3480.
17. Glazko, A. J., A. W. Kinkell, W. C. Alegnani, and E. L. Holmes. 1968. An evaluation of the absorption characteristics of different chloramphenicol preparations in normal subjects. Clin. Pharmacol. Ther. 9:472-483.
18. Goodman, J. L., C. Nelson, B. Vitale, J. E. Madigan, J. S. Dumler, T. J. Kurtti, and U. G. Munderloch. 1996. Direct cultivation of the causative agent of human granulocytic ehrlichiosis. N. Engl. J. Med. 334:209-215.
19. Hardalo, C. J., V. Quagliarello, and J. S. Dumler. 1995. Human granulocytic ehrlichiosis in Connecticut: report of a fatal case. Clin. Infect. Dis. 21:910-914.
20. Heep, M., D. Beck, E. Bayerdorffer, and N. Lehn. 1999. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob. Agents Chemother. 43:1497-1499.
21. Horowitz, H. W., T.-C. Hsieh, M. E. Aguero-Rosenfeld, F. Kalantarpour, I. Chowdhury, G. P. Wormser, and J. M. Wu. 2001. Antimicrobial susceptibility of Ehrlichia phagocytophila. Antimicrob. Agents Chemother. 45:786-788.
22. Klein, M. B., C. M. Nelson, and J. L. Goodman. 1997. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins. Antimicrob. Agents Chemother. 41:76-79.
23. Lotric-Furlan, S., M. Petrovec, T. A. Zupanc, W. L. Nicholson, J. W. Summer, J. E. Childs, and F. Strle. 1998. Human granulocytic ehrlichiosis in Europe: clinical and laboratory findings for four patients from Slovenia. Clin. Infect. Dis. 27:424-428.
24. Massung, R. F., J. H. Owens, D. Ross, K. D. Reed, M. Petrovec, A. Bjoersdorff, R. T. Coughlin, G. A. Beltz, and C. I. Murphy. 2000. Sequence analysis of the ank gene of granulocytic ehrlichiae. J. Clin. Microbiol. 38:2917-2922.
25. Maurin, M., C. Abergel, and D. Raoult. 2001. DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp. Antimicrob. Agents Chemother. 45:2098-2105.
26. Maurin, M., and D. Raoult. 1996. Optimum treatment of intracellular infection. Drugs 52:45-59.
27. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
28. Ogden, N. H., Z. Woldehiwet, and C. A. Hart. 1998. Granulocytic ehrlichiosis: an emerging or rediscovered tick-borne disease? J. Med. Microbiol. 47:475-482.
29. Owens, R. C., and P. G. Ambrose. 2000. Clinical use of the fluoroquinolones. Med. Clin. North Am. 84:1447-1469.
30. Smilack, J. D. 1999. The tetracyclines. Mayo Clin. Proc. 74:727-729.
31. Sumption, K. J., D. J. M. Wright, S. J. Cutler, and B. A. S. Dale. 1995. Human ehrlichiosis in the UK. Lancet 346:1487-1488.
32. Van Doddenburgh, A., A. P. Van Dam, and E. Fikrig. 1999. Human granulocytic ehrlichiosis in Western Europe. N. Engl. J. Med. 340:1214-1215.
33. Vester, B., and S. Douthwaite. 2001. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob. Agents Chemother. 45:1-12.
34. Wormser, G., D. McKenna, M. Aguero-Rosenfeld, et al. 1995. Human granulocytic ehrlichiosis - New York, 1995. Morb. Mortal. Wkly. Rep. 44:593-595.